Healthcare Industry News: IPLEX
News Release - January 3, 2007
Luminex Signs Agreement With Fisher HealthCareLuminex Gains Access To Major Diagnostic Sales Network
AUSTIN, Texas, Jan. 3 (HSMN NewsFeed) -- Luminex Corporation (Nasdaq: LMNX ), a leading multIPLEX solution developer, announces the signing of a Development and Supply Agreement with Fisher HealthCare, part of Thermo Fisher Scientific Inc. (NYSE: TMO ). The agreement provides Fisher HealthCare with access to Luminex xMAP®-based technology in the U.S. and offers Luminex a broad new customer sales channel for xMAP-based instruments and assays.
Luminex and Fisher HealthCare will jointly identify promising molecular diagnostic applications for Luminex to develop and manufacture on behalf of Fisher HealthCare, taking advantage of the proven assay multiplexing capabilities of Luminex's xMAP technology. Fisher HealthCare is the premier healthcare channel to laboratory customers in the United States, with a multi- layered sales force, access to key clinical accounts and an extensive logistics network. Specific terms of the agreement were not disclosed.
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Luminex's xMAP technology received the 2005 Clinical Diagnostics Technology of the Year Award from Frost & Sullivan. The Company was named in the 2005 Deloitte Fast 500 of fastest-growing technology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO ) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual sales of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward- looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.